Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMeprobamate
Identification
- Name
- Meprobamate
- Accession Number
- DB00371 (APRD01095)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
- Structure
Structure for Meprobamate (DB00371)
- Synonyms
- Meprobamat
- Meprobamate
- Meprobamato
- Meprobamatum
- Meprobamic acid
- External IDs
- DEA No. 2820
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataEquanil Tablets 400mg Tablet Oral Wyeth Ayerst Canada Inc. 1994-12-31 2000-03-07 Canada 
Meditran 400mg Tablet Oral Medic Laboratory LtÉe 1959-12-31 1996-09-09 Canada Meprobamate Tab 400mg Tablet Oral Pro Doc Limitee 1959-12-31 2001-10-15 Canada Meprobamate Tab 400mg Tablet Oral Duchesnay Inc. 1978-12-31 2001-10-15 Canada Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataApo Meprobamate Tab 400mg Tablet Oral Apotex Corporation 1975-12-31 2001-10-09 Canada Meprobamate Tablet 400 mg/1 Oral Alembic Pharmaceuticals Limited 2013-07-23 Not applicable US 
Meprobamate Tablet 200 mg/1 Oral Alembic Pharmaceuticals Limited 2013-07-23 Not applicable US Meprobamate Tablet 400 mg/1 Oral Alembic Pharmaceuticals Inc. 2016-03-31 Not applicable US Meprobamate Tablet 200 mg/1 Oral Alembic Pharmaceuticals Inc. 2016-03-31 Not applicable US Meprobamate Tablet 400 mg/1 Oral Taro Pharmaceuticals U.S.A., Inc. 2011-05-23 Not applicable US Meprobamate Tablet 200 mg/1 Oral Taro Pharmaceuticals U.S.A., Inc. 2011-05-23 Not applicable US Meprobamate Tablet 400 mg/1 Oral Heritage 2009-05-01 2018-01-10 US Meprobamate Tablet 200 mg/1 Oral Heritage 2009-05-01 2018-01-10 US Meprobamate Tablet 400 mg/1 Oral Taro Pharmaceutical Industries, Ltd. 2011-05-23 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 282 Mep Tab Meprobamate (200 mg) + Acetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg) Tablet Oral Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1959-12-31 1998-08-14 Canada Equagesic Meprobamate (200 mg/1) + Acetylsalicylic acid (325 mg/1) Tablet Oral Mikart, Inc. 2008-01-15 Not applicable US Equagesic Tablets Meprobamate (200 mg) + Acetylsalicylic acid (250 mg) + Ethoheptazine citrate (75 mg) Tablet Oral Wyeth Ayerst Canada Inc. 1995-12-31 1997-01-14 Canada - International/Other Brands
- Equanil (Wyeth) / Meprospan / Miltown (Wallace Laboratories)
- Categories
- UNII
- 9I7LNY769Q
- CAS number
- 57-53-4
- Weight
- Average: 218.2502
Monoisotopic: 218.126657074 - Chemical Formula
- C9H18N2O4
- InChI Key
- NPPQSCRMBWNHMW-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
- IUPAC Name
- 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
- SMILES
- CCCC(C)(COC(N)=O)COC(N)=O
Pharmacology
- Indication
For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
- Associated Conditions
- Pharmacodynamics
Meprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer) but it is less sedating at effective doses. Meprobamate exhibits some anticonvulsant effects in absence seizures; however, it is reported to potentially exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.
- Mechanism of action
Meprobamate's mechanism of action is not fully understood; in animal studies, meprobamate is reported to act at multiple sites in the central nervous system, such as the thalamus and limbic system. It binds to the GABAA receptors, leading to inhibitory effects on the neurons transmitting signals in the reticular formation and spinal cord. Consequently, effects such as sedation and altered perception of pain are observed.
Target Actions Organism AGamma-aminobutyric acid receptor subunit alpha-1 agonistHumans AGamma-aminobutyric acid receptor subunit alpha-2 agonistHumans AGamma-aminobutyric acid receptor subunit alpha-3 agonistHumans AGamma-aminobutyric acid receptor subunit alpha-4 agonistHumans AGamma-aminobutyric acid receptor subunit alpha-5 agonistHumans AGamma-aminobutyric acid receptor subunit alpha-6 agonistHumans AGABA(A) Receptor positive allosteric modulatorHumans - Absorption
Well absorbed from the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Meprobamate undergoes hepatic metabolism.
- Route of elimination
- Not Available
- Half life
Plasma half-life is about 10 hours.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. There have been a case of death resulting from oral ingestion of 12 g of meprobamate. One case study reports the consumption of 40 g of meprobamate resulting in successful survival.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Capecitabine Action Pathway Drug action Capecitabine Metabolism Pathway Drug metabolism - Pharmacogenomic Effects/ADRs
- Not Available
Unlock Additional Data
Additional Data Available
Adverse Effects
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn more Additional Data Available
Contraindications
Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn more Additional Data Available
Blackbox Warnings
Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when Meprobamate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when Meprobamate is combined with 4-Bromo-2,5-dimethoxyamphetamine. 4-Methoxyamphetamine The risk or severity of adverse effects can be increased when Meprobamate is combined with 4-Methoxyamphetamine. 5-methoxy-N,N-dimethyltryptamine The risk or severity of adverse effects can be increased when Meprobamate is combined with 5-methoxy-N,N-dimethyltryptamine. 7-Nitroindazole The risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Meprobamate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Acepromazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine. Aceprometazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine. Acetazolamide The risk or severity of adverse effects can be increased when Meprobamate is combined with Acetazolamide. Acetophenazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Acetophenazine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Avoid alcohol.
- Take with or without food. Food does not significantly affect absorption.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014515
- KEGG Drug
- D00376
- PubChem Compound
- 4064
- PubChem Substance
- 46508142
- ChemSpider
- 3924
- RxNav
- 6760
- ChEBI
- 6761
- ChEMBL
- CHEMBL979
- ZINC
- ZINC000001530701
- Therapeutic Targets Database
- DAP001507
- PharmGKB
- PA450377
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Meprobamate
- ATC Codes
- N05BC51 — Meprobamate, combinationsN05CX01 — Meprobamate, combinations
- N05CX — Hypnotics and sedatives in combination, excl. barbiturates
- N05C — HYPNOTICS AND SEDATIVES
- N05 — PSYCHOLEPTICS
- N — NERVOUS SYSTEM
- MSDS
- Download (52.6 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline llc
- Medpointe pharmaceuticals medpointe healthcare inc
- Wyeth ayerst laboratories
- Ferndale laboratories inc
- Alra laboratories inc
- Teva pharmaceuticals usa inc
- Alembic ltd
- Barr laboratories inc
- Elkins sinn div ah robins co inc
- Heather drug co inc
- Impax laboratories inc
- Invagen pharmaceuticals inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Ivc industries inc dba inverness medical nutritionals group
- Lannett co inc
- Lederle laboratories div american cyanamid co
- Km lee laboratories inc
- Mallard inc
- Mk laboratories inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Nexgen pharma inc
- Parke davis div warner lambert co
- L perrigo co
- Pharmavite pharmaceuticals
- Purepac pharmaceutical co
- Private formulations inc
- Roxane laboratories inc
- Sandoz inc
- Scherer laboratories inc
- Solvay pharmaceuticals
- Stanlabs pharmaceutical co sub simpak corp
- Tablicaps inc
- Usl pharma inc
- Valeant pharmaceuticals international
- Vangard laboratories inc div midway medical co
- Watson laboratories inc
- West ward pharmaceutical corp
- Whiteworth towne paulsen inc
- Halsey drug co inc
- Packagers
- C.O. Truxton Inc.
- Calvin Scott and Co. Inc.
- Dispensing Solutions
- Doctor Reddys Laboratories Ltd.
- GlaxoSmithKline Inc.
- Group Health Cooperative
- Heritage Pharmaceuticals
- InvaGen Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mikart Inc.
- Nexgen Pharma Inc.
- PD-Rx Pharmaceuticals Inc.
- Prescript Pharmaceuticals
- Qualitest
- United Research Laboratories Inc.
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral Tablet Oral Tablet Oral 200 mg/1 Tablet Oral 400 mg/1 - Prices
Unit description Cost Unit Mepron 750 mg/5ml Suspension 5.41USD ml Mepron 750 mg/5 ml suspension 4.95USD ml Meprobamate 200 mg tablet 1.42USD tablet Meprobamate 400 mg tablet 0.84USD tablet Meprozine 50-25 mg capsule 0.78USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Unlock Additional DataUS6649659 Yes 2003-11-18 2017-01-10 US US4981874 No 1991-01-01 2009-08-15 US CA2152615 No 2001-10-16 2013-12-23 Canada CA1336266 No 1995-07-11 2012-07-11 Canada Additional Data Available- Filed On
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 105 °C PhysProp water solubility 4700 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 0.70 HANSCH,C ET AL. (1995) logS -1.67 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 2.47 mg/mL ALOGPS logP 1.06 ALOGPS logP 0.93 ChemAxon logS -2 ALOGPS pKa (Strongest Acidic) 15.17 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 104.64 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 53.04 m3·mol-1 ChemAxon Polarizability 22.65 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9534 Blood Brain Barrier + 0.9864 Caco-2 permeable - 0.5731 P-glycoprotein substrate Non-substrate 0.5282 P-glycoprotein inhibitor I Non-inhibitor 0.8781 P-glycoprotein inhibitor II Non-inhibitor 0.9033 Renal organic cation transporter Non-inhibitor 0.945 CYP450 2C9 substrate Non-substrate 0.9108 CYP450 2D6 substrate Non-substrate 0.8961 CYP450 3A4 substrate Non-substrate 0.7032 CYP450 1A2 substrate Non-inhibitor 0.8381 CYP450 2C9 inhibitor Non-inhibitor 0.8799 CYP450 2D6 inhibitor Non-inhibitor 0.8764 CYP450 2C19 inhibitor Non-inhibitor 0.8754 CYP450 3A4 inhibitor Non-inhibitor 0.8735 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8914 Ames test Non AMES toxic 0.8706 Carcinogenicity Non-carcinogens 0.7304 Biodegradation Not ready biodegradable 0.965 Rat acute toxicity 2.4075 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9943 hERG inhibition (predictor II) Non-inhibitor 0.9322
Spectra
- Mass Spec (NIST)
- Download (10.1 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Carbamate esters
- Alternative Parents
- Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA4
- Uniprot ID
- P48169
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-4
- Molecular Weight
- 61622.645 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA6
- Uniprot ID
- Q16445
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-6
- Molecular Weight
- 51023.69 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- ChEMBL Compound Report Card [Link]
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 11:40
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates